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Background. HLA class-I alleles differ in their ability to control HIV replication through cell-mediated immune responses. No
consistent associations have been found between the breadth of Cytotoxic T Lymphocytes (CTL) responses and the control of
HIV-1, and it is unknown whether the size or distribution of the viral proteome-wide epitope repertoire, i.e., the intrinsic ability
to present fewer, more or specific viral epitopes, could affect clinical markers of disease progression. Methodology/Principal
Findings. We used an epitope prediction model to identify all epitope motifs in a set of 302 HIV-1 full-length proteomes
according to each individual’s HLA (Human Leukocyte Antigen) genotype. The epitope repertoire, i.e., the number of predicted
epitopes per HIV-1 proteome, varied considerably between HLA alleles and thus among individual proteomes. In a subgroup of
270 chronically infected individuals, we found that lower viral loads and higher CD4 counts were associated with a larger
predicted epitope repertoire. Additionally, in Gag and Rev only, more epitopes were restricted by alleles associated with low
viral loads than by alleles associated with higher viral loads. Conclusions/Significance. This comprehensive analysis puts
forth the epitope repertoire as a mechanistic component of the multi-faceted HIV-specific CTL response. The favorable impact
on markers of disease status of the propensity to present more HLA binding peptides and specific proteins gives impetus to
vaccine design strategies that seek to elicit responses to a broad array of HIV-1 epitopes, and suggest a particular focus on
Gag.
Citation: Rolland M, Heckerman D, Deng W, Rousseau CM, Coovadia H, et al (2008) Broad and Gag-Biased HIV-1 Epitope Repertoires Are Associated
with Lower Viral Loads. PLoS ONE 3(1): e1424. doi:10.1371/journal.pone.0001424
INTRODUCTION
Although attempts to correlate the breadth of the CTL antiviral
response and control of HIV-1 infection in vivo have been
equivocal [1,2,3,4,5,6,7,8,9], accumulating evidence support the
beneficial role of Gag-specific CTL responses in HIV-1 contain-
ment [2,10,11,12,13,14,15,16,17,18] - alluding to differences in
antiviral efficacy among specific CD8
+ T-cell responses. Addition-
ally, certain HLA genes are associated with different rates of
disease progression [19,20,21,22,23,24,25,26,27,28,29]. In partic-
ular, HLA alleles B*27 and B*57 seem to confer a survival benefit
whereas HLA B*35_Px confers a survival disadvantage [22].
While HLA-B alleles appear to impact disease progression more
than other alleles [25], possessing heterologous HLA alleles, and
thus possibly allowing the individual to present broader arrays of
epitopes, has also been associated with delayed/slower disease
progression [24].
The extent of polymorphisms in HIV sequences and in HLA
loci underscores that a vast array of HLA/viral peptide
combinations can be generated during infection. HIV-1 is
characterized by its extensive diversity both among and within
infected individuals due to its extreme capacity to mutate, its
persistent replication, and the important role of CD8
+ lymphocyte
responses in driving viral evolution [30,31,32]. In addition, the
HLA region is one of the most polymorphic loci in the human
genome. HLA class I molecules are codominantly expressed on
antigen-presenting cells such that all six allotypes (if the person
expresses heterologous HLA-A, -B and -C proteins) can present
viral epitopes.
The fine-mapping of epitopes, typically 9 amino acid (AA) long
but ranging from 8 to 11 AA, together with data on their binding
properties to HLA molecules, has allowed definition of HLA class
I allele-specific sequence motifs that are able to prime virus-
specific CD8
+ T-cell responses. Consistent associations between
HLA alleles and disease outcomes suggest an underlying
mechanistic function, and prompted us to question whether the
scope of the epitope repertoire contributes to the composite
effectiveness of the CTL response. ‘‘Epitope repertoire’’ here refers
to all viral peptide sequences that fulfill HLA class I allele-specific
binding motifs for a specific whole HIV-1 proteome.
Epitope mapping data has been used to develop computational
methods of epitope prediction, which are important for the
development of diagnostic tools and the design and evaluation of
vaccines. Identification of novel HIV-1 epitopes simultaneously
fuels our greater understanding of the immune recognition of the
HIV proteome and incremental improvements of epitope
prediction algorithms [33,34,35,36]. Here, we predicted HLA
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and designed to leverage data across HLA alleles and/or
supertypes ([37] available at http://atom.research.microsoft.
com/hlabinding/hlabinding.aspx). The prediction method pro-
duces approximately 10% false positive results when set to yield
10% false negatives.
We predicted the epitope repertoire in 302 full-length HIV-1
proteomes, isolated from 302 untreated individuals infected with
HIV-1 subtype C and B, based on each subject’s HLA genotype
[32,38,39,40,41,42,43,44]. We report that a larger epitope
repertoire was associated with lower levels of viremia. Further-
more, alleles associated with reduced viral loads tended to target
particularly Gag when compared to alleles associated with a lack
of control of viral replication.
RESULTS
The size of the epitope repertoire differed between
HLA alleles and thereby between autologous HIV-1
proteomes
Scanning 302 HIV-1 proteomes, corresponding to 2,718 HIV-1
protein sequences, resulted in the identification of 22,779 epitope
motifs, including 8,208 experimentally defined CTL epitopes
compiled in databases prior to our study (the latter two figures
include redundancies from detection of the same epitopes in
multiple individuals). The number of predicted epitopes varied
greatly among alleles, i.e., between 1 and 47 per allele per
proteome, and henceforth among individuals ranging between 14
and 186 per proteome (mean=75; median=72). Given that the
vast majority of known epitopes were defined experimentally using
peptides corresponding to subtype B, more CTL epitopes are
known for subtype B than for subtype C. Thus in turn, more
motifs were identified in proteomes from subtype B (mean=113
per proteome, including 60 previously known epitopes) than in
subtype C (mean=71, including 23 previously known epitopes).
To rule out this experimental bias toward HIV-1 subtype B in our
study, we verified that the number of epitopes restricted by an
allele was not associated with the allele frequency in the
population. There were no associations between the number of
epitopes restricted by an allele and its frequency in the population
in a subgroup of 32 individuals from the Seattle Primary Infection
Cohort (r
2=0.0280; p=0.2307), nor in a subtype C infected
South African cohort from Durban (r
2=0.0347; p=0.1998;
n=270 individuals) or in a representative Sub-Saharan population
(r
2=0.0319; p=0.2197). However, there was a positive relation-
ship between the number of epitopes and the allele frequency in
the overall North American population (r
2=0.1153; p=0.0129;
n=1021 individuals), likely reflecting the focus of HIV/AIDS
research on this population. Interestingly, HLA B*27, an allele
repeatedly associated with favorable disease outcomes [22] and
found 3 times in our dataset, presented the third largest epitope
repertoire with 42 predicted epitopes per HIV-1 proteome, i.e.,
over 3 times the average repertoire size (Mean number of
epitopes/HLA allele=13.87; Confidence Interval (CI) with
a=0.99, Lower CI=9.46; Upper CI=18.27).
Relationship between epitope repertoires and
clinical data
We compared numbers of predicted epitopes per proteome to viral
loads and CD4 counts in subtype C infected individuals from the
South African cohort. We found that the more epitopes predicted
for an individual, the lower the observed viral load (r
2=0.0446,
p=0.0005; Spearman’s correlation factor: Rho=20.1751,
p=0.0039). In particular, we found a stronger negative relation-
ship between the size of the epitope repertoire and the viral loads
among the 81 individuals who had CD4 counts above 400, i.e.,
when we excluded from the analysis the individuals with vanishing
T cell numbers, and presumably function (r
2=0.1009, p=0.0038;
Spearman’s correlation factor: Rho=20.3090, p=0.0050)
(Figure 1A). Additionally, larger epitope repertoires were associ-
ated with higher CD4 counts (r
2=0.0620, p=0.0250; Spearman’s
Rho=0.1549, p=0.0395) (Figure 1B). A relatively weaker
association was observed for CD4 than for viral loads, possibly
due to CD4 counts being available for only 177 of the 270
individuals evaluated.
By grouping individuals according to their plasma viral loads,
we found significantly different numbers of predicted HIV-1
epitopes in individuals within the lowest (,16,437 viral RNA
copies/ml; n=67) and highest (.186,250 copies; n=67) quartiles.
HIV-1 proteomes from individuals in the quartile with the lowest
viral load had a mean number of 80 predicted epitopes, compared
to 67 in the highest quartile (p= 0.0047) (Figure 1C). There was
also a trend for individuals with higher CD4 counts to have more
predicted epitopes, the mean number was 76 for individuals in the
highest quartile (n=45; CD4.521.5), and 65 in the lowest
quartile (n=44; CD4,234.5) (p=0.0686).
The least frequent alleles in the cohort were found to be
associated with lower viral loads (Spearman’s Rho=0.2880;
p=0.0448), in agreement with Trachtenberg and colleagues
[21]. And, we found a trend indicating that HLA alleles restricting
larger repertoires were associated with lower viral loads in HLA-
matched individuals (Figure 1D) (Spearman’s Rho=20.2952;
p=0.0517).
Distribution of epitope repertoires vary between
HLA alleles associated with different viral loads
Next, we ranked HLA alleles by the average viral loads of subjects
in the Durban cohort: the quartile with the lowest viral loads
(,125,437 viral copies; mean=65,384; median=58,229) includ-
ed 12 alleles, herein referred as ‘‘good’’ alleles; the quartile with
the highest viral loads (.320,643 viral copies; mean=971,587;
median=531,20) included 12 ‘‘bad’’ alleles. Interestingly, the
distribution of predicted epitopes among HIV-1 proteins revealed
that ‘‘good’’ HLA alleles focused more on Gag (Figure 2A) and less
on Nef (Figure 2B). For ‘‘good’’ HLA alleles, predicted Gag
epitopes increased 1.69 fold (p=0.036) compared to the
distribution found for ‘‘bad’’ HLA alleles, while predicted Nef
epitopes decreased 2.35 fold (p=0.038). When analyzed by
individual protein, Gag- and Rev-specific repertoires showed
more epitopes restricted by ‘‘good’’ HLA alleles than by ‘‘bad’’
ones, whereas there were more epitopes restricted by ‘‘bad’’ HLA
alleles than by ‘‘good’’ ones in Nef, Env, Pol, Tat, Vif, Vpu, and
also Vpr (albeit marginally) (Figure 2C). Nef- and Gag-specific
epitope repertoires showed similar percentages of epitopes
restricted by ‘‘good’’ alleles, however, the proportion of epitopes
restricted by ‘‘bad’’ alleles was significantly higher in Nef
compared to its proportion in Gag.
DISCUSSION
We systematically examined the immunogenic potential of HIV-1
at the population level through in silico estimation of the epitope
repertoire of 302 HIV-1 proteomes. The number of predicted
HIV-1 epitopes per proteome varied considerably between HLA
alleles and thereby among individuals. Additionally, there were
more epitopes identified in subtype B viruses than in subtype C,
reflecting the existing bias of databases for inclusion of data from
HIV-1 Epitope Repertoire
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while we demonstrated that our analysis was not confounded by
this experimental bias, it also highlights the need for better
characterization of CTL responses against HIV-1 subtype C in the
affected population (i.e., with typical motifs and HLA allele
restrictions). Nonetheless, limitations to epitope prediction analyses
intrinsically include biases derived from their training datasets, the
fact that certain epitopes are not optimally defined or have
incorrect HLA alleles restrictions (e.g., due to linkage disequilib-
rium) and pervasive of HLA class I allele promiscuity [45]. Despite
those potential shortcomings, our findings corroborate those from
immunological studies in this cohort. Principally, individuals with
high viral loads tended to target preferentially Env and
Accesssory/Regulatory proteins [18,27,44,46], while individuals
with low viral loads tended to make strong CTL responses against
Gag [18,27,44,46]. Additionally, by comparison with subtype B
infected individuals Frahm and colleagues showed the importance
of subdominant CTL responses for the control of replication in
subtype C infected individuals [18,27,44,46]. Collectively, those
studies lend support to our in silico approach, especially in the
context of a relatively limited knowledge of CTL responses in
HIV-1 subtype C infection.
We also explored whether specificities of the epitope
repertoires could affect clinical markers of disease progression.
By integrating HIV-1 proteome-wide epitope mining to clinical
and laboratory data in a South African cohort, our data showed
a trend indicating that the number of HLA/epitope pairs was
correlated both negatively with viral loads and positively with
CD4 counts. Hence, HLA alleles associated with lower viral
load in this cohort, referred to as ‘‘good’’ alleles, tended to
present larger predicted epitope repertoires, than HLA alleles
associated with high viremias, the ‘‘bad’’ alleles. This suggests
that the inherent ability to present more epitopes could be a
contributing factor to better clinical disease status. Alternatively,
certain sets of epitopes may be needed to control the infection
and thus, the more epitope motifs presented, the more likely
individuals are to cover those epitopes. Our data alludes to a
mechanistic paradigm in the cell-mediated immune response,
supporting the intuitive assertion that control of HIV infection
would capitalize on a broad repertoire while control would be
stymied by a narrower epitopic pool. However, a nettlesome
HIV characteristic is that despite eliciting relatively broad CTL
responses, this generally does not result in the containment of
the virus. Although attempts to correlate the breadth of the CTL
antiviral response and control of HIV-1 infection in vivo have
been equivocal [1,2,3,4,5,6,7,8,9,18], it could nonetheless be
beneficial for the host to have a larger epitopic pool to choose
from – maybe not as a means to broaden the CTL response but
rather to increase the probability of producing the more limited,
effective set of CTL responses, since a diverse panoply of
epitopes can be available for CTL recognition simultaneously
and/or successively.
Figure 1. HIV-1 epitope repertoires and clinical data. Putative epitopes were identified in silico within full-length autologous HIV-1 proteomes and
combined with previously described optimally defined CTL epitopes found in the LANL and IEDB databases. (A) and (B) respectively show the log viral
loads and the CD4 counts plotted as a function of the number of predicted HIV-1 epitopes identified per proteome for the individuals with CD4
counts above 400 (n=81). (C) Shows the number of predicted HIV-1 epitopes for individuals belonging to the highest (mean=65) and lowest
(mean=76) viremia quartile. (D) Shows the average viral loads of individuals presenting a specific allele as a function of the average number of HIV-1
predicted epitopes for that allele (only alleles presented by at least 3 individuals in the South-African cohort were included).
doi:10.1371/journal.pone.0001424.g001
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solely on its breadth, it is widely believed that CTL escape has a
major impact on disease outcome. As such, the limited epitope
repertoire we identified for individuals/alleles associated with high
viremia could reflect escape mutations that eliminated binding
motifs from the autologous viral sequences.
In addition to quantitative distinctions, there were also
qualitative differences between epitope repertoires restricted by
specific HLA alleles: Those associated with better control of HIV
replication were likely to present more Gag epitopes in their
repertoire than ‘‘bad’’ alleles did; ‘‘bad’’ alleles were instead
associated with a higher proportion of Nef epitopes. Interestingly,
a recent study by Kiepiela and colleagues showed that Nef-specific
CTL responses were associated with higher viral loads, unlike
Gag-specific CTL responses, which were associated with lower
viral burdens [2,44]. While numerous reports have emphasized
that CTL responses targeting Gag are the most tightly associated
with the control of HIV replication [2,10,11,12,13,14,15,16,17],
little is known about the underlying mechanism. Our study
indicates that ‘‘good’’ alleles preferentially target Gag, and that
within Gag there is an over-representation of epitopes restricted by
‘‘good’’ alleles instead of ‘‘bad’’ ones, as seen for all other HIV-1
proteins (except Rev). Interestingly, our results using clinical and
laboratory data from infected individuals agrees with a very recent
in silico study showing that HLA alleles with a low Relative Hazard
(RH) of disease progression preferentially presented p24 epitopes
[47]. Thus, discordant viral loads depending on specific protein
targeting are apparently associated with particular HLA allele
restriction sets for each protein. Nonetheless, this leaves open the
question of what accounts for the beneficial effect on viremia: CTL
responses focusing specifically on Gag, or CTL responses restricted
by certain ‘‘good’’ alleles, or both.
The potential shortcomings of in silico epitope predictions
cannot be entirely dismissed. And, notwithstanding the composite
aspect of the cell-mediated immune response and the difficulty in
ascertaining the relative importance of each attribute, evidence
that the CTL response is in part mechanically predetermined
could be significant in on-going efforts to define more palatable
criteria of the immune response to assist vaccine design. Our
findings are therefore relevant for vaccine design as they suggest
Figure 2. Distribution of epitopes by HLA alleles and by protein. Distribution of epitopes among HIV-1 proteins for HLA alleles associated with
lowest/highest viral loads. The ratio of predicted epitopes predicted for each protein corresponded to the number of epitope-fulfilling motifs
identified in each protein over the total number of epitopes identified for the whole proteome. (A) Shows the distribution of epitopes for ‘‘good’’
alleles, i.e., those associated with the lowest viral loads in the cohort (lowest quartile: VL,125,437; mean=65,384; median=58,229). (B) Shows the
epitope distribution for ‘‘bad’’ alleles, those associated with the highest viral loads in the cohort (highest quartile: VL.320,643; mean=971,587;
median=531,208). For each allele belonging to a quartile, average values per allele were calculated based on the viral loads of HLA-matched
individuals). (C) Illustrates the percentage of epitopes restricted by ‘‘good’’ and ‘‘bad’’ HLA alleles for each protein.
doi:10.1371/journal.pone.0001424.g002
HIV-1 Epitope Repertoire
PLoS ONE | www.plosone.org 4 January 2008 | Issue 1 | e1424the need to 1) maximize the number of possible epitopes to include
in a vaccine candidate and to 2) direct the immune response
toward Gag rather than Nef proteins [44,48,49].
MATERIALS AND METHODS
Dataset
We evaluated 302 HIV-1 full-length plasma-derived genome
sequences along with the HLAgenotypes of the infected individuals.
270 subjects were from Durban (South Africa) infected with HIV-1
subtype C [38,39] and 32 subjects from the Seattle PIC cohort
(USA)[43] infected with HIV-1 subtype B [32,40,41,42](and
unpublished). Immunological and clinical data (viral loads and
CD4 counts) were available at the time of virus sampling for a
subgroup of the Durban cohort; details were described elsewhere
[44]. HIV-1 amino acid sequences were derived for all recognized
protein coding sequences of the 302 HIV-1 genomes. HLA allele
frequencies in different ethnicities were obtained at http://www.
ncbi.nlm.nih.gov/projects/mhc/ihwg.cgi?cmd=PRJOV&ID=9.
Epitope Prediction
We employed an implementation of our previously described
model [37] that uses logistic regression and leverages data across
HLA alleles to predict CTL epitopes (http://atom.research.
microsoft.com/hlabinding/hlabinding.aspx). The predictor was
trained on all T-cell epitope data from the LANL [50] and IEDB
(http://www.immuneepitope.org/home.do) databases in July
2006. Examples of non-epitopes (nine for each positive example)
were obtained by randomly sampling proteins from UniProt [51].
Eight-, nine-, ten-, and eleven-mer predictors were trained
separately. The prior probability of an epitope for each allele
was set to 0.1. The prior probability of an epitope for a given allele
of length k was proportional to the number of positive examples
found for that length-allele combination in the datasets. A peptide-
HLA pair was deemed a potential epitope if its posterior
probability according to the predictor was greater than 0.5.
Statistical analysis
Statistical analyses were done using JMPH version 5.1.2.
Relationships between 2 variables were analyzed using Spear-
man’s correlation factor Rho. Parametric Student’s t tests were
used to compare each pair of means.
ACKNOWLEDGMENTS
We thank Brian Birditt and Brandon S. Maust for help with data
gathering, and Dr. Joshua T. Herbeck for valuable discussions and critical
reading of the manuscript.
Author Contributions
Conceived and designed the experiments: MR. Performed the experi-
ments: HC DH WD KB. Analyzed the data: CB JM DH MR CR.
Contributed reagents/materials/analysis tools: PG BW CB HC CR KB.
Wrote the paper: PG BW JM DH MR.
REFERENCES
1. Frahm N, Korber BT, Adams CM, Szinger JJ, Draenert R, et al. (2004)
Consistent cytotoxic-T-lymphocyte targeting of immunodominant regions in
human immunodeficiency virus across multiple ethnicities. J Virol 78:
2187–2200.
2. Zuniga R, Lucchetti A, Galvan P, Sanchez S, Sanchez C, et al. (2006) Relative
dominance of Gag p24-specific cytotoxic T lymphocytes is associated with
human immunodeficiency virus control. J Virol 80: 3122–3125.
3. Masemola A, Mashishi T, Khoury G, Mohube P, Mokgotho P, et al. (2004)
Hierarchical targeting of subtype C human immunodeficiency virus type 1
proteins by CD8+ T cells: correlation with viral load. J Virol 78: 3233–3243.
4. Gea-Banacloche JC, Migueles SA, Martino L, Shupert WL, McNeil AC, et al.
(2000) Maintenance of large numbers of virus-specific CD8+ T cells in HIV-
infected progressors and long-term nonprogressors. J Immunol 165: 1082–1092.
5. Edwards BH, Bansal A, Sabbaj S, Bakari J, Mulligan MJ, et al. (2002)
Magnitude of functional CD8+ T-cell responses to the gag protein of human
immunodeficiency virus type 1 correlates inversely with viral load in plasma.
J Virol 76: 2298–2305.
6. Betts MR, Ambrozak DR, Douek DC, Bonhoeffer S, Brenchley JM, et al. (2001)
Analysis of total human immunodeficiency virus (HIV)-specific CD4(+)a n d
CD8(+) T-cell responses: relationship to viral load in untreated HIV infection.
J Virol 75: 11983–11991.
7. Addo MM, Yu XG, Rathod A, Cohen D, Eldridge RL, et al. (2003)
Comprehensive epitope analysis of human immunodeficiency virus type 1
(HIV-1)-specific T-cell responses directed against the entire expressed HIV-1
genome demonstrate broadly directed responses, but no correlation to viral load.
J Virol 77: 2081–2092.
8. Musey L, Hughes J, Schacker T, Shea T, Corey L, et al. (1997) Cytotoxic-T-cell
responses, viral load, and disease progression in early human immunodeficiency
virus type 1 infection. N Engl J Med 337: 1267–1274.
9. Liu Y, McNevin J, Zhao H, Tebit DM, McSweyn M, et al. (2007) Evolution of
HIV-1 CTL epitopes: Fitness-Balanced Escape. ePub.
10. Novitsky V, Gilbert P, Peter T, McLane MF, Gaolekwe S, et al. (2003)
Association between virus-specific T-cell responses and plasma viral load in
human immunodeficiency virus type 1 subtype C infection. J Virol 77: 882–890.
11. Ogg GS, Jin X, Bonhoeffer S, Dunbar PR, Nowak MA, et al. (1998)
Quantitation of HIV-1-specific T lymphocytes and plasma viral load of viral
RNA. Science 279: 2103–2106.
12. Riviere Y, McChesney MB, Porrot F, Tanneau-Salvadori F, Sansonetti P, et al.
(1995) Gag-specific cytotoxic responses to HIV type 1 are associated with a
decreased risk of progression to AIDS-related complex or AIDS. AIDS Res
Hum Retroviruses 11: 903–907.
13. Geldmacher C, Currier JR, Herrmann E, Haule A, Kuta E, et al. (2007) CD8 T-
cell recognition of multiple epitopes within specific Gag regions is associated with
maintenance of a low steady-state viremia in human immunodeficiency virus
type 1-seropositive patients. J Virol 81: 2440–2448.
14. Sacha JB, Chung C, Rakasz EG, Spencer SP, Jonas AK, et al. (2007) Gag-
specific CD8+ T lymphocytes recognize infected cells before AIDS-virus
integration and viral protein expression. J Immunol 178: 2746–2754.
15. Ramduth D, Chetty P, Mngquandaniso NC, Nene N, Harlow JD, et al. (2005)
Differential immunogenicity of HIV-1 clade C proteins in eliciting CD8+ and
CD4+ cell responses. J Infect Dis 192: 1588–1596.
16. Crawford H, Prado JG, Leslie A, Hue S, Honeyborne I, et al. (2007)
Compensatory Mutation Partially Restores Fitness and Delays Reversion of
Escape Mutation within the Immunodominant Hla-B*5703-Restricted Gag
Epitope in Chronic Hiv-1 Infection. J Virol.
17. Streeck H, Schweighardt B, Jessen H, Allgaier RL, Wrin T, et al. (2007) Loss of
HIV-1-specific T-cell responses associated with very rapid HIV-1 disease
progression. Aids 21: 889–891.
18. Honeyborne I, Prendergast A, Pereyra F, Leslie A, Crawford H, et al. (2007)
Control of human immunodeficiency virus type 1 is associated with HLA-B*13
and targeting of multiple gag-specific CD8+ T-cell epitopes. J Virol 81:
3667–3672.
19. Carrington M, O’Brien SJ (2003) The influence of HLA genotype on AIDS.
Annu Rev Med 54: 535–551.
20. Migueles SA, Sabbaghian MS, Shupert WL, Bettinotti MP, Marincola FM, et al.
(2000) HLA B*5701 is highly associated with restriction of virus replication in a
subgroup of HIV-infected long term nonprogressors. Proc Natl Acad Sci U S A
97: 2709–2714.
21. Trachtenberg E, Korber B, Sollars C, Kepler TB, Hraber PT, et al. (2003)
Advantage of rare HLA supertype in HIV disease progression. Nat Med 9:
928–935.
22. O’Brien SJ, Gao X, Carrington M (2001) HLA and AIDS: a cautionary tale.
Trends Mol Med 7: 379–381.
23. Gao X, Nelson GW, Karacki P, Martin MP, Phair J, et al. (2001) Effect of a
single amino acid change in MHC class I molecules on the rate of progression to
AIDS. N Engl J Med 344: 1668–1675.
24. Carrington M, Nelson GW, Martin MP, Kissner T, Vlahov D, et al. (1999) HLA
and HIV-1: heterozygote advantage and B*35-Cw*04 disadvantage [see
comments]. Science 283: 1748–1752.
25. Kiepiela P, Leslie AJ, Honeyborne I, Ramduth D, Thobakgale C, et al. (2004)
Dominant influence of HLA-B in mediating the potential co-evolution of HIV
and HLA. Nature 432: 769–775.
26. Frahm N, Adams S, Kiepiela P, Linde CH, Hewitt HS, et al. (2005) HLA-B63
presents HLA-B57/B58-restricted cytotoxic T-lymphocyte epitopes and is
associated with low human immunodeficiency virus load. J Virol 79:
10218–10225.
HIV-1 Epitope Repertoire
PLoS ONE | www.plosone.org 5 January 2008 | Issue 1 | e142427. Frahm N, Kiepiela P, Adams S, Linde CH, Hewitt HS, et al. (2006) Control of
human immunodeficiency virus replication by cytotoxic T lymphocytes targeting
subdominant epitopes. Nat Immunol 7: 173–178.
28. MacDonald KS, Embree JE, Nagelkerke NJ, Castillo J, Ramhadin S, et al.
(2001) The HLA A2/6802 supertype is associated with reduced risk of perinatal
human immunodeficiency virus type 1 transmission. J Infect Dis 183: 503–506.
29. MacDonald KS, Fowke KR, Kimani J, Dunand VA, Nagelkerke NJ, et al.
(2000) Influence of HLA supertypes on susceptibility and resistance to human
immunodeficiency virus type 1 infection. J Infect Dis 181: 1581–1589.
30. Jones NA, Wei X, Flower DR, Wong M, Michor F, et al. (2004) Determinants of
human immunodeficiency virus type 1 escape from the primary CD8+ cytotoxic
T lymphocyte response. J Exp Med 200: 1243–1256.
31. Allen TM, Altfeld M, Geer SC, Kalife ET, Moore C, et al. (2005) Selective
escape from CD8+ T-cell responses represents a major driving force of human
immunodeficiency virus type 1 (HIV-1) sequence diversity and reveals
constraints on HIV-1 evolution. J Virol 79: 13239–13249.
32. Liu Y, McNevin J, Cao J, Zhao H, Genowati I, et al. (2006) Selection on the
human immunodeficiency virus type 1 proteome following primary infection.
J Virol 80: 9519–9529.
33. Suhrbier A, Schmidt C, Fernan A (1993) Prediction of an HLA B8-restricted
influenza epitope by motif. Immunology 79: 171–173.
34. Larsen MV, Lundegaard C, Lamberth K, Buus S, Brunak S, et al. (2005) An
integrative approach to CTL epitope prediction: a combined algorithm
integrating MHC class I binding, TAP transport efficiency, and proteasomal
cleavage predictions. Eur J Immunol 35: 2295–2303.
35. Lundegaard C, Nielsen M, Lund O (2006) The validity of predicted T-cell
epitopes. Trends Biotechnol 24: 537–538.
36. Louzoun Y, Vider T, Weigert M (2006) T-cell epitope repertoire as predicted
from human and viral genomes. Mol Immunol 43: 559–569.
37. Heckerman D, Kadie C, Listgarten J (2006) Leveraging information across HLA
alleles/supertypes improves epitope prediction. ;Tenth Annual International Confer-
ence on Research in Computational Molecular Biology (RECOMB). Venice, Italy.
38. Rousseau C, Birditt BA, McKay AR, Stoddard JN, Lee TC, et al. (2006) Large-
scale amplification, cloning and sequencing of near full-length HIV-1 subtype C
genomes. J Virol Methods 136: 118–125.
39. Rousseau CM, Learn GH, Bhattacharya T, Nickle DC, Heckerman D, et al.
(2007) Extensive Intra-subtype Recombination in South African HIV-1 Subtype
C Infections. J Virol 81: 4492–4500.
40. Liu SL, Schacker T, Musey L, Shriner D, McElrath MJ, et al. (1997) Divergent
patterns of progression to AIDS after infection from the same source: human
immunodeficiency virus type 1 evolution and antiviral responses. J Virol 71:
4284–4295.
41. Learn GH, Muthui D, Brodie SJ, Zhu T, Diem K, et al. (2002) Virus population
homogenization following acute human immunodeficiency virus type 1
infection. J Virol 76: 11953–11959.
42. Truong HM, Berrey MM, Shea T, Diem K, Corey L (2002) Concordance
between HIV source partner identification and molecular confirmation in acute
retroviral syndrome. J Acquir Immune Defic Syndr 29: 232–243.
43. Schacker T, Collier AC, Hughes J, Shea T, Corey L (1996) Clinical and
epidemiologic features of primary HIV infection. Ann Intern Med 125:
257–264.
44. Kiepiela P, Ngumbela K, Thobakgale C, Ramduth D, Honeyborne I, et al.
(2007) CD8+ T-cell responses to different HIV proteins have discordant
associations with viral load. Nat Med 13: 46–53.
45. Frahm N, Yusim K, Suscovich TJ, Adams S, Sidney J, et al. (2007) Extensive
HLA class I allele promiscuity among viral CTL epitopes. Eur J Immunol 37:
2419–2433.
46. Leslie A, Price DA, Mkhize P, Bishop K, Rathod A, et al. (2006) Differential
selection pressure exerted on HIV by CTL targeting identical epitopes but
restricted by distinct HLA alleles from the same HLA supertype. J Immunol 177:
4699–4708.
47. Borghans JA, Molgaard A, de Boer RJ, Kesmir C (2007) HLA Alleles Associated
with Slow Progression to AIDS Truly Prefer to Present HIV-1 p24. PLoS ONE
2: e920.
48. Rolland M, Nickle DC, Mullins JI (2007) A new, core elements approach to
vaccine immunogen design. PLoS Pathogens: In press.
49. Altfeld M, Allen TM (2006) Hitting HIV where it hurts: an alternative approach
to HIV vaccine design. Trends Immunol 27: 504–510.
50. Korber BTM, Brander C, Haynes BF, Koup R, Moore JP, et al. (2005) HIV
Molecular Immunology 2005. ;Los Alamos National Laboratory, Theoretical
Biology and Biophysics, Los Alamos, New Mexico. LA-UR 06-0036.
51. Wu CH, Apweiler R, Bairoch A, Natale DA, Barker WC, et al. (2006) The
Universal Protein Resource (UniProt): an expanding universe of protein
information. Nucleic Acids Res 34: D187–191.
HIV-1 Epitope Repertoire
PLoS ONE | www.plosone.org 6 January 2008 | Issue 1 | e1424